We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Device Developed Could Improve Cancer Detection

By LabMedica International staff writers
Posted on 02 Jun 2016
Circulating tumor cells (CTCs) are malignant cells that have escaped from a primary tumor into the bloodstream with the potential to form metastases at anatomically distant sites.

A newly developed method to isolate cancer cells that have escaped from a tumor could soon pave the way for improved diagnosis and treatment. More...
The simple process involves a special device that squeezes cells in a blood sample through tiny funnels, which drive the cancer cells and blood cells into separate streams based on differences in their size and softness.

Scientists at University of British Columbia (Vancouver, BC, Canada) used polydimethylsiloxane (PDMS) to fabricate the microfluidic device. Cell separation processes involved initially filling the microfluidic device using phosphate buffered saline (PBS) with 0.2% Pluronic F127 to prevent nonspecific adsorption of cells to the wall of the device. Whole blood samples from patients with metastatic castrate-resistant prostate cancer (mCRPC) and four healthy control donors were infused through the device through the sample inlet, while buffer solutions were infused through the buffer and oscillation inlets.

For the assessment of the role of cell deformability in separation performance the scientists measured the cell size, suspending the cell samples in PBS and visualized using an Ti-U inverted microscope (Nikon, Tokyo, Japan) and Nikon’s CCD camera DS-2MBW. The size of CTCs and leukocytes from mCRPC patients were measured from the bright field image of the separated cells in suspension by drawing a circle on the outer edge of each target cells. At least 25 CTCs and leukocytes were measured for each mCRPC data set.

The scientists were able to show in patients with metastatic castration-resistant prostate cancer, where CTCs are not significantly larger than leukocytes; CTCs can be captured based on deformability at 25× greater yield than with the conventional CellSearch system (Raritan, NJ, USA). Finally, the CTCs separated using this approach are collected in suspension and are available for downstream molecular characterization.

Kim N. Chi, MD, the director of clinical research at the B.C. Cancer Agency a co-author of the study said, “In the first study, the device was able to capture more than 90% of the cells. Importantly, in patient samples the device captured about 25 times the number of cancer cells and produced fewer false positives compared to the conventional CellSearch system, which also analyzes blood samples.” The study was published on April 7, 2016, in the journal Small.

Related Links:
University of British Columbia
Nikon
CellSearch

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.